ICYMI: Josh Skydel Joseph Ross & I are in The Hill speaking about the financial & clinical impacts of allowing unproven drugs to remain on the market & what reforms to the accelerated approval pathway should be included in the U.S. FDA user fee legislation. thehill.com/blogs/congress…

NEW in STAT today Joseph Ross & I argue that reformulations of existing medications are more abt profits than patient health. But the other story here is about incentivizing the right type of innovation that meets the needs of the 21st century vs slightly tweaking medications

Also excited that our abstract on #neutrophils in #lupusnephritis was selected for poster presentation at #ACR23 American College of Rheumatology to be presented by Josh Skydel! A wonderful collaboration with Andrea Fava and Lucas Salas.

Beyond excited to be joining Yale Rheumatology in July... and to join Joseph Ross and Reshma Ramachandran in New Haven! #rheum

New JAMA study w/ Alissa, Reshma Ramachandran Jennifer E. Miller Maryam Mooghali, MD, MSc Joseph Ross! Emory Public Health Yale_CRRIT Are FDA-approved cancer drugs supported by pivotal trials w/ adequate representation of minoritized groups associated w/ slower clinical development times?1/7

Our JAMA study finds diverse pivotal trials are not associated w slower enrollment or clinical development times in oncology, as often feared w/ Joshua D. Wallach Joseph Ross Reshma Ramachandran Maryam Mooghali, MD, MSc led by Alissa Wong #clinicaltrialdiversity Yale Internal Medicine jamanetwork.com/journals/jama/…

Thrilled that our amazing postdoc Maryam Mooghali, MD, MSc will be staying here for a few more years, having matched here at Yale Internal Medicine! Congratulations, Maryam! #Match2024

In our new study BMJMedicine, CRRIT Postdoc Maryam Mooghali, MD, MSc examined NCCN guidelines’ recommendations for oncology drug treatments with U.S. FDA accelerated approval. Reshma Ramachandran Joseph Ross Joshua D. Wallach Aaron Mitchell Josh Skydel bmjmedicine.bmj.com/content/3/1/e0…

Honored to have received the Resident Research Award from Dartmouth Internal Medicine this past week, and grateful for all the mentors and friends I’ve met in my 3 years here. Next stop: @Yale Rheum/Allergy!

The FDA is now officially cutting out the requirement of switching studies for biosimilars to obtain interchangeability designations - it's a move that's been in the works for years and is part of FDA's push to eliminate interchangeability entirely endpts.com/fda-makes-it-e…